Reductase activity of 17beta-hydroxysteroid oxidoreductase in prostatic tumors of different histological structure.
Reductase activity of 17beta-hydroxysteroid oxidoreductase in biopsy specimens of prostatic cancer and benign hyperplasia, and prostatic intraepithelial neoplasia and serum concentrations of testosterone, 5alpha-dihydrotestosterone, 4-androstene-3,17-dione were compared in patients and healthy individuals. Reductase activities of 17beta-hydroxysteroid oxidoreductase in soluble fraction of prostatic biopsy specimens decreased in the following order: prostatic cancer>prostatic intraepithelial neoplasia>>benign prostatic hyperplasia. No differences in serum concentrations of testosterone, 5alpha-dihydrotestosterone, 4-androstene-3,17-dione between these three groups of patients were found, while the mean serum concentration of these androgens in patients with prostatic tumors did not surpass the threshold normal values for men. Hence, high reductase activity of 17beta-hydroxysteroid oxidoreductase can be associated with pathogenetic mechanisms of human malignant prostatic tumors.
Degtyar
V G
VG
N. N. Blokhin National Center for Cancer Research, Russian Academy of Medical Sciences, Moscow.
Babkina
T V
TV
Kazantseva
I A
IA
Morozov
A P
AP
Trapeznikova
M F
MF
Kushlinskii
N E
NE
D015067:17-Hydroxysteroid Dehydrogenases / Q000032:analysis / Q000378:metabolism*; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000097:blood; D001706:Biopsy; D013196:Dihydrotestosterone / Q000097:blood; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000201:enzymology* / Q000601:surgery; D019048:Prostatic Intraepithelial Neoplasia / Q000201:enzymology* / Q000473:pathology* / Q000601:surgery; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000473:pathology* / Q000601:surgery; D013739:Testosterone / Q000097:blood
D013196:Dihydrotestosterone; D013739:Testosterone; D015067:17-Hydroxysteroid Dehydrogenases; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase